Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma
We describe two patients with recurrent, refractory, and progressive advanced fibrolamellar hepatocellular carcinoma (HCC) following orthotopic liver transplantation who received programmed cell death protein 1 (PD‐1) inhibitor, nivolumab, on a patient access, off‐label basis. Both rapidly developed irreversible acute liver rejection shortly after starting therapy, and ultimately died. While checkpoint inhibitors clearly have tremendous potential as a targeted therapy, they should be avoided or used with extreme caution in the context of an organ transplant.
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Brian D. Friend, Robert S. Venick, Sue V. McDiarmid, Xiaoyan Zhou, Bita Naini, Hanlin Wang, Douglas G. Farmer, Ronald W. Busuttil, Noah Federman Tags: BRIEF REPORT Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Transplant | Pediatrics | Transplant Surgery | Transplants | Urology & Nephrology